



07-31-01

0360  
PATENT APPLICATION**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Paszty, et al.

Serial No.: 09/818,954

Group Art Unit No.: 1653

Filed: March 27, 2001

Examiner: Not Assigned Yet

For: Beta-Like Glycoprotein Hormone Polypeptide and  
Heterodimer

Docket No.: A-676B

**RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to a "Notice to File Corrected Application Papers" dated May 30, 2001, noting the need to correct the following informalities on the above-identified application, we enclose the following.

Enclosed herewith are: 1) substitute drawings in compliance with 37 CFR 1.84, 2) an Attorney Statement indicating that the content of the sequence listing information recorded in computer readable form is identical to the paper copy of the sequence listing and that it includes no new matter, 3) a substitute computer readable form of the sequence listing, 4) a paper copy of the sequence listing, and 5) a copy of the Notice to file corrected application papers in this application.

No fees should be due, however, the Commissioner is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

Richard J. Mazza  
Attorney/Agent for Applicant(s)  
Registration No.: 27,657  
Phone: (805) 447-4112  
Date: July 30, 2001Please send all future correspondence to:  
US Patent Operations/RJM  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799**EXPRESS MAIL CERTIFICATE**"Express Mail" mail labeling number: EL198798545USDate of Deposit: July 30, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum  
Printed Name  
Signature



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/818,954	03/27/2001	Christopher J.R. Paszty	A-676B

CONFIRMATION NO. 9125

21069  
AMGEN INCORPORATED  
MAIL STOP 27-4-A  
ONE AMGEN CENTER DRIVE  
THOUSAND OAKS, CA 91320-1799

## FORMALITIES LETTER



\*OC00000006128038\*

Date Mailed: 05/30/2001

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

---

*A copy of this notice MUST be returned with the reply.*

  
\_\_\_\_\_  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE